Abstract
miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.
Keywords: Cancer, cancer therpay, microRNA, transcription, Dicer, RNA-induced silencing complex (RISC), translation, genome, apoptotic pathways, metastasis, leukemia, lymphoma, hepatocellular carcinoma, oncogenes, oncosuppressor genes
Current Molecular Medicine
Title: miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy
Volume: 12 Issue: 1
Author(s): M. Garofalo, C. Quintavalle, G. Romano, C. M. Croce and G. Condorelli
Affiliation:
Keywords: Cancer, cancer therpay, microRNA, transcription, Dicer, RNA-induced silencing complex (RISC), translation, genome, apoptotic pathways, metastasis, leukemia, lymphoma, hepatocellular carcinoma, oncogenes, oncosuppressor genes
Abstract: miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.
Export Options
About this article
Cite this article as:
Garofalo M., Quintavalle C., Romano G., M. Croce C. and Condorelli G., miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy, Current Molecular Medicine 2012; 12 (1) . https://dx.doi.org/10.2174/156652412798376170
DOI https://dx.doi.org/10.2174/156652412798376170 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Overview of the Synthesis of Optically Active 3-Amino-2-Hydroxy-4-Phenylbutyric Acids, Key Intermediates for Numerous Bioactive Compounds
Mini-Reviews in Organic Chemistry Double Point Modified Analogs of Vitamin D as Potent Activators of Vitamin D Receptor
Current Pharmaceutical Design Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Current Gene Therapy Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
Current Pharmacogenomics Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Endoglin-Targeted Cancer Therapy
Current Drug Delivery Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Kit: Molecule of Interest for the Diagnosis and Treatment of Mastocytosis and other Neoplastic Disorders
Current Cancer Drug Targets Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
Current Drug Metabolism Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets